Teva’s TEV-408 Hits Key Phase IIa Endpoint in Celiac Disease Study

Israeli company on verge of breakthrough in celiac drug development

Teva has reported significant progress in its pipeline of innovative drugs, with TEV '408, the company's experimental drug for treating celiac disease, meeting its primary endpoint in a Phase 2a clinical trial. Teva considers the drug an asset with significant commercial potential, having previously estimated that peak sales of the celiac treatment could reach approximately […] The post Israeli company on verge of breakthrough in celiac drug dev…

Teva’s TEV-408 Hits Key Phase IIa Endpoint in Celiac Disease Study

Teva Pharmaceutical Industries (NYSE:TEVA) reported positive topline results from a Phase IIa gluten-challenge study of TEV-408, its anti-IL-15 antibody candidate for celiac disease, with the company saying the treatment met its primary endpoint and showed statistically significant effects on key me

Teva posts mid-stage trial win for celiac disease drug (TEVA)

Teva Pharmaceutical (TEVA) stock gains as the company succeeds in a mid-stage trial for its celiac disease therapy developed with Royalty Pharma (RPRX). Read more here.

Teva Announces Positive Topline Results from Phase 2a Study in Celiac Disease for Its Anti-IL-15 Antibody, Further Validating Its Pipeline-in-a-Product Potential

Teva-discovered TEV ‘408, a novel anti-IL-15 monoclonal antibody, demonstrated statistically significant and clinically meaningful prevention of gluten-induced intestinal damage vs placebo following a single subcutaneous dose.TEV ‘408 was well-tolerated with no safety signals observed to date.Together with the vitiligo program,…

Teva claims success in celiac study; BioMarin, Ascendis settle patent dispute

Teva believes the therapy has “pipeline-in-a-product” potential. Elsewhere, a high-stakes trial was paused and GSK advanced a competitor to Moderna’s flu shot.